CA2725911A1 - Methods of treating a meiotic kinesin-associated disease - Google Patents

Methods of treating a meiotic kinesin-associated disease Download PDF

Info

Publication number
CA2725911A1
CA2725911A1 CA 2725911 CA2725911A CA2725911A1 CA 2725911 A1 CA2725911 A1 CA 2725911A1 CA 2725911 CA2725911 CA 2725911 CA 2725911 A CA2725911 A CA 2725911A CA 2725911 A1 CA2725911 A1 CA 2725911A1
Authority
CA
Canada
Prior art keywords
kinesin
hset
agent
meiotic
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2725911
Other languages
English (en)
French (fr)
Inventor
David Pellman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2725911A1 publication Critical patent/CA2725911A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA 2725911 2008-05-30 2009-05-28 Methods of treating a meiotic kinesin-associated disease Abandoned CA2725911A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5759008P 2008-05-30 2008-05-30
US61/057,590 2008-05-30
PCT/US2009/045406 WO2009155025A1 (en) 2008-05-30 2009-05-28 Methods of treating a meiotic kinesin-associated disease

Publications (1)

Publication Number Publication Date
CA2725911A1 true CA2725911A1 (en) 2009-12-23

Family

ID=41110533

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2725911 Abandoned CA2725911A1 (en) 2008-05-30 2009-05-28 Methods of treating a meiotic kinesin-associated disease

Country Status (12)

Country Link
US (3) US8629118B2 (cg-RX-API-DMAC10.html)
EP (1) EP2315594B1 (cg-RX-API-DMAC10.html)
JP (3) JP5735417B2 (cg-RX-API-DMAC10.html)
KR (1) KR20110022000A (cg-RX-API-DMAC10.html)
CN (1) CN102316877A (cg-RX-API-DMAC10.html)
AU (1) AU2009260527A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0912043A2 (cg-RX-API-DMAC10.html)
CA (1) CA2725911A1 (cg-RX-API-DMAC10.html)
EA (1) EA201071422A1 (cg-RX-API-DMAC10.html)
ES (1) ES2633930T3 (cg-RX-API-DMAC10.html)
MX (1) MX2010012931A (cg-RX-API-DMAC10.html)
WO (1) WO2009155025A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012931A (es) 2008-05-30 2011-02-24 Dana Farber Cancer Inst Inc Metodos para tratar una enfermedad asociada con quinesina meiotica.
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US20150309031A2 (en) * 2013-12-05 2015-10-29 Novazoi Theranostics Compositions and methods for prognosis and treatment of cancer
WO2015130953A1 (en) * 2014-02-28 2015-09-03 Novazoi Theranostics, Inc. Method for determining the risk profile of neoplastic tissue
CN113456633A (zh) * 2021-06-11 2021-10-01 广西医科大学 红海海绵素a在制备抗肺癌侵袭转移药物中的应用
AU2023205435A1 (en) 2022-01-10 2024-08-22 Cancer Research Horizons Substituted heterocycles as hset inhibitors
CN115327125A (zh) * 2022-07-14 2022-11-11 宁波大学 一种蛋白质inf2在制备肝癌诊断标志物中的应用
CN120265629A (zh) 2022-11-07 2025-07-04 默克专利股份公司 被取代的双环和三环hset抑制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU4367700A (en) * 1999-04-20 2000-11-02 Cytokinetics, Inc. Human kinesins and methods of producing and purifying human kinesins
US6410254B1 (en) * 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) * 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7416856B2 (en) * 1999-05-18 2008-08-26 Cytokinetics, Inc. High sensitivity assay for detection of nucleoside diphosphate production
US6743599B1 (en) * 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
WO2002078639A2 (en) 2001-03-29 2002-10-10 Bristol-Myers Squibb Company A method of treating proliferative diseases using eg5 inhibitors
US20040009156A1 (en) * 2001-10-12 2004-01-15 Christoph Reinhard Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
US7163927B2 (en) 2002-05-23 2007-01-16 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20050100508A1 (en) 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20070026424A1 (en) * 2005-04-15 2007-02-01 Powell Charles A Gene profiles correlating with histology and prognosis
AR062200A1 (es) 2006-08-04 2008-10-22 Aeterna Zentaris Gmbh Derivados de antraceno y su uso para el tratamiento de emfermedades tumorales bengnas y malingnas
US20080051463A1 (en) * 2006-08-04 2008-02-28 Aeterna Zentaris Gmbh Anthracene compounds and their use for treating benign and malignant tumor disorders
WO2008132752A2 (en) 2007-05-01 2008-11-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for predicting cancer metastasis
MX2010012931A (es) 2008-05-30 2011-02-24 Dana Farber Cancer Inst Inc Metodos para tratar una enfermedad asociada con quinesina meiotica.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy

Also Published As

Publication number Publication date
US20150111786A1 (en) 2015-04-23
US8629118B2 (en) 2014-01-14
JP5735417B2 (ja) 2015-06-17
CN102316877A (zh) 2012-01-11
WO2009155025A1 (en) 2009-12-23
ES2633930T3 (es) 2017-09-26
JP2015131813A (ja) 2015-07-23
US20140106344A1 (en) 2014-04-17
BRPI0912043A2 (pt) 2019-09-24
EP2315594B1 (en) 2017-05-17
US9645136B2 (en) 2017-05-09
EA201071422A1 (ru) 2011-08-30
JP2011525174A (ja) 2011-09-15
AU2009260527A1 (en) 2009-12-23
US20110190374A1 (en) 2011-08-04
JP2016169224A (ja) 2016-09-23
JP6132409B2 (ja) 2017-05-24
MX2010012931A (es) 2011-02-24
US8962592B2 (en) 2015-02-24
JP6184556B2 (ja) 2017-08-23
EP2315594A1 (en) 2011-05-04
KR20110022000A (ko) 2011-03-04

Similar Documents

Publication Publication Date Title
US9645136B2 (en) Methods of treating a meiotic kinesin-associated disease
Liu et al. Kinesin-12, a mitotic microtubule-associated motor protein, impacts axonal growth, navigation, and branching
Deakin et al. Paxillin inhibits HDAC6 to regulate microtubule acetylation, Golgi structure, and polarized migration
Bonazzi et al. Successive post‐translational modifications of E‐cadherin are required for InlA‐mediated internalization of Listeria monocytogenes
US20100267626A1 (en) Methods and compositions for measuring wnt activation and for treating wnt-related cancers
Yoshida et al. CDC6 interaction with ATR regulates activation of a replication checkpoint in higher eukaryotic cells
Zhang et al. USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1
Gonzalez‐Nieves et al. Rsu1 contributes to regulation of cell adhesion and spreading by PINCH1‐dependent and‐independent mechanisms
Yoneda et al. A collapsin response mediator protein 2 isoform controls myosin II-mediated cell migration and matrix assembly by trapping ROCK II
Gau et al. The VASP–profilin1 (Pfn1) interaction is critical for efficient cell migration and is regulated by cell–substrate adhesion in a PKA-dependent manner
Hoock et al. RITA modulates cell migration and invasion by affecting focal adhesion dynamics
Storey et al. Activity-dependent internalization of Glun2B-containing NMDARs is required for synaptic incorporation of Glun2A and synaptic plasticity
US20140248635A1 (en) Alpha-tubulin acetyltransferase
Janssens et al. Characterization of EVL-I as a protein kinase D substrate
Mukherjee et al. Ca2+/Calmodulin Dependent Protein Kinase Kinase-2 (CaMKK2) promotes Protein Kinase G (PKG)-dependent actin cytoskeletal assembly to increase tumor metastasis
Odii Roles of Transglutaminase 2 in development of drug resistance and metastasis by cancer cells
da Silva Lopes The roles of tubulin post-translational modifications in cancer
Lopes The roles of tubulin post-translational modifications in cancer
Farrell Phosphorylated Ubiquitin in the DNA damage response
WO2015187929A1 (en) Treatment of fragile x syndrome by inhibition of cdh1-apc
Polusani Gene regulation through gap junction intercellular communication and its consequences for cell behavior
Cescutti TopBP1 functions with 53BP1 in the G1 DNA damage response
Edmond et al. Post-translational modifications of SRSF2 control cell fate decision in response to cisplatin
O'Rourke Cep192: An essential protein for centrosomal microtubule nucleation
Neumayer Defining a role for TPX2 in the nucleus–Regulation of the DNA damage response

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20140528